World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0006495182
Reproduction Date:

Title: Trilostane  
Author: World Heritage Encyclopedia
Language: English
Subject: Metyrapone, Cyanoketone, 20α,22R-Dihydroxycholesterol, Cyproterone acetate, Cortodoxone
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
  • Veterinary use (U.S.)
Routes of
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 8 hours
CAS Registry Number  N
ATC code H02
PubChem CID:
DrugBank  YesY
ChemSpider  YesY
Chemical data
Formula C20H27NO3
Molecular mass 329.433 g/mol

Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.[1][2]

It was withdrawn from human use in the United States market in April 1994.[3][4] The drug was previously available in the United Kingdom for use in humans under the brand name Modrenal for the treatment of Cushing's disease and for breast cancer.[5][6][7] It was approved in the United States in 2008 for the treatment of Cushing's disease (hyperadrenocorticism) in dogs under the brand name Vetoryl.[8] It was available by prescription in the UK under the Vetoryl brand name for some time before it was approved in the US.[9] The drug is also used to treat the skin disorder Alopecia X in dogs.[3][10][11] It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.[12][13] In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss. Trilostane should not be given to a dog that:

  1. has kidney or liver disease;[9][14]
  2. takes certain medications used to treat heart disease;
  3. is pregnant, nursing or intended for breeding [9][14]

The safety and effectiveness of trilostane were shown in several studies. Success was measured by improvements in both blood test results and physical symptoms (increased appetite and activity level, and decreased panting, thirst and urination).[7][15]

Only one other drug, Anipryl (veterinary brand name) selegiline, is FDA-approved to treat Cushing's disease in dogs, but only to treat uncomplicated, pituitary-dependent Cushing's.[16] The only previous treatment for the disease was the use of Mitotane (brand name Lysodren) off-label.[15][17]

It has been used as a progesterone inhibitor.[18]

A number of compounding pharmacies in the US sell the product. Since the US approval of Vetoryl in December 2008,[8] compounding pharmacies are no longer able to use a bulk drug product for compounding purposes, but must prepare the compounded drug from Vetoryl.[19]

It is a 3β-hydroxysteroid dehydrogenase inhibitor.[20]


The compound is prepared from testosterone in a four-step synthesis.


  1. ^
  2. ^
  3. ^ a b
  4. ^
  5. ^
  6. ^
  7. ^ a b (PDF)
  8. ^ a b
  9. ^ a b c
  10. ^ (PDF)
  11. ^ (PDF)
  12. ^ (PDF)
  13. ^
  14. ^ a b (PDF)
  15. ^ a b
  16. ^
  17. ^
  18. ^
  19. ^
  20. ^

External links

  • Trilostane (Vetoryl) information from Veterinary Medicines Directorate, UK. Includes precautionary use regarding concurrent medical conditions, possible side effects, and possible interaction with other drugs. (PDF)

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.